Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
Funding
Not specified
Deadline
--
Days
--
Hrs
--
Min
--
Sec
May 07, 2026
Posted Nov 18, 2024 (458 days ago)
Closes May 7, 2026 (in 76 days)
Grant Details
Opportunity Number
PAR-25-111
CFDA / ALN
93.279, 93.313, 93.855, 93.865
Opportunity Category
Discretionary (D)
Funding Category
ED, HL, ISS
Funding Instrument
Grant (G)
Cost Sharing
No Cost Sharing (No)
Eligibility
State governments (00)
County governments (01)
City or township governments (02)
Special district governments (04)
Independent school districts (05)
Public and State controlled institutions of higher education (06)
Native American tribal governments (Federally recognized) (07)
Public housing authorities / Indian housing authorities (08)
Native American tribal organizations (11)
Nonprofits having a 501(c)(3) status with the IRS (12)
Nonprofits without 501(c)(3) status (13)
Private institutions of higher education (20)
For-profit organizations other than small businesses (22)
Small businesses (23)
Others (25)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description
The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant women, lactating women, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating women, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating women, fetuses, neonates, and children, including those with disabilities.
Related Grants
Extension of the World Trade Center Health Registry (U50)
Centers for Disease Control and Prevention - ERA
$9,480,000
BJA FY25 The Kevin and Avonte Program: Reducing Injury and Death of Missing Individuals with Dementia and Developmental Disabilities
Bureau of Justice Assistance
$150,000
Cooperative Agreement for affiliated Partner with the North Atlantic Coast Cooperative Ecosystem Studies Unit
Geological Survey
$498,392
New World Screwworm Grand Challenge
Animal and Plant Health Inspection Service
$5,000,000
FY 2026 National Infrastructure Investments
69A345 Office of the Under Secretary for Policy
$25,000,000
OVC FY25 Preventing Trafficking of Girls
Office for Victims of Crime
$497,000